Litcius/Paper detail

Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia

Nicholas J. Short, Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall, Amber Gibson, Nitin Jain, Fadi Haddad, Lewis Nasr, Kayleigh Marx, Caitlin R. Rausch, J. Michael Savoy, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian

2023Clinical Lymphoma Myeloma & Leukemia23 citationsDOIOpen Access PDF

Topics & Concepts

BlinatumomabMedicineLymphoblastic LeukemiaPhiladelphia chromosomeCD22OncologyInternal medicineLeukemiaB cellImmunologyGeneticsChromosomal translocationGeneAntibodyBiologyAcute Lymphoblastic Leukemia researchCAR-T cell therapy researchChronic Myeloid Leukemia Treatments
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia | Litcius